REDFIELD, Iowa (DTN) -- Following U.S. Secretary of Agriculture Tom Vilsack's announcement last week of USDA's approval of vaccine testing for H5N1 for cattle, South Dakota-based animal health vaccine manufacturer Medgene has responded to the notice.
"We have a number of companies that have been working on vaccines, and one company has presented sufficient information to the USDA to allow me to authorize the first field trial for a vaccine for cattle for H5N1 for safety purposes," Vilsack said. The field trial will be done in hopes of moving forward for safe and effective use of the vaccine.
OUTBREAK CONTINUES, NOW IN CALIFORNIA
This also happened as California announced its first H5N1 cases at three dairies in the Central Valley. This makes for 14 states affected by the outbreak and 197 confirmed cases as of Sept. 4, 2024.
"We have been preparing for this possibility since earlier this year when HPAI (highly pathogenic avian influenza) detections were confirmed at dairy farms in other states," said California Department of Food and Agriculture Secretary Karen Ross. "Our extensive experience with HPAI in poultry has given us ample preparation and expertise to address this incident, with workers' health and public health as our top priorities. This is a tough time for our dairy farmers given the economic challenges they're facing in a dynamic market, so I want to assure them that we are approaching this incident with the utmost urgency."
SUCCESSFUL TESTING MEANS PRODUCTION FOLLOWS
Medgene has been successful in prescription platform vaccine production in the swine, cattle, rabbit and deer industries, both in the U.S. and internationally. Chief Operating Office Tom Halbur said in a news release, "This is great news for us, for the CVB (USDA Center for Veterinary Biologics) and more importantly, the dairy industry. Our technology is founded on being able to respond to disease challenges faster. Our protocol satisfies the states requirements and we're looking forward to doing our part in supporting both the necessary regulatory policies and the needs of the dairy industry."
The CVB Notice allows for vaccine studies to be conducted outside of containment facilities and has the potential to accelerate agency licensure of H5N1 vaccines in dairy cows.
Medgene's proprietary model of production was developed using modern advances in vaccine science. The expected result of this work will be conditional or full licensure by the CVB to produce and distribute an H5N1 vaccine after it has been proven safe and effective in dairy cattle.
Jennifer Carrico can be reached at jennifer.carrico@dtn.com
Follow her on social platform X @JennCattleGal
(c) Copyright 2024 DTN, LLC. All rights reserved.